Form 4: Carlsmed CCO William Durall Granted 71,429 Stock Options

Carlsmed, Inc.'s Chief Commercial Officer, William Scott Durall, was granted 71,429 stock options with a $15 exercise price, vesting quarterly over four years.

Summary

• William Scott Durall, Chief Commercial Officer of Carlsmed, Inc. (CARL), was granted 71,429 stock options.
• The options have an exercise price of $15 per share.
• Vesting for these stock options will commence in equal installments on each quarterly anniversary of July 22, 2025, the grant date.
• All granted stock options are scheduled to be fully vested on the fourth anniversary of the grant date, contingent upon Mr. Durall's continuous service.
• The expiration date for these stock options is July 9, 2035.
• Following this transaction, Mr. Durall beneficially owns 296,008 derivative securities.

Sentiment

Score: 6

Explanation: The grant of stock options is a standard compensation practice that aligns executive incentives with shareholder value, generally viewed as a neutral to slightly positive event for company governance and executive retention.

Positives

• The stock option grant serves as an incentive for the Chief Commercial Officer, William Scott Durall, to remain with the company.
• Aligns the Chief Commercial Officer's financial interests with the long-term performance and shareholder value of Carlsmed, Inc.

Negatives

• The future exercise of these options could lead to dilution for existing shareholders.

Future Outlook

The vesting schedule of the stock options over four years indicates an expectation of continued service from the Chief Commercial Officer, aligning his long-term commitment with the company's future performance.

Industry Context

The grant of stock options to a key executive like the Chief Commercial Officer is a common and standard practice within the corporate landscape, particularly in the medical technology or biotech sectors, used to attract, retain, and incentivize top talent by aligning their compensation with company performance.

Related Party Transactions

• The grant of stock options to William Scott Durall, the Chief Commercial Officer, constitutes a related party transaction as it involves compensation provided by the company to a key executive.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefits from aligned executive incentives for long-term company growth.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• The granted stock options will vest in equal installments on each quarterly anniversary of July 22, 2025, over a four-year period, contingent on continuous service.

Key Dates

Keywords

Carlsmed, CARL, Stock Options, Executive Compensation, Form 4, William Scott Durall, Chief Commercial Officer, Equity Grant, Vesting